COCP earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -1.27. Updated 2026-07-23.
Cocrystal Pharma (COCP) Research Hub
Cocrystal Pharma (COCP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.24 USD (0.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.27, market cap 0.01B. This hub links to the full technical, earnings and options research available for COCP.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.24 USD (0.00%) |
| 52-week range | 0.76 USD – 1.29 USD |
| Trend regime | Range |
| 14-day RSI | 80 (Overbought) |
| Trailing P/E | -1.27 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for COCP
Covered Call on COCP: how it works, illustrative setup around the real 1.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on COCP: how it works, illustrative setup around the real 1.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on COCP: how it works, illustrative setup around the real 1.24 USD price, max profit/loss, breakeven and when to use it. Educational.
COCP technical analysis: range, last 1.24 USD, RSI 80, 52w range 0.76 USD–1.29 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is COCP in?
Cocrystal Pharma (COCP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is COCP in an uptrend or downtrend?
As of 2026-09-11, COCP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is COCP's trailing P/E ratio?
COCP's trailing P/E is -1.27, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does COCP next report earnings?
COCP is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.17 USD.